Regulus Therapeutics Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 19,569 12,700 13,789 8,601
Cost of Revenue - - - -
Gross Profit 19,569 12,700 13,789 8,601
Operating Expenses
Research and Development 29,942 20,342 17,289 20,178
Sales, General and Admin. 7,429 4,932 3,637 3,921
Non-Recurring Items - - - -
Other - - - -
Operating Income (17,802) (12,574) (7,137) (15,498)
Income From Continuing Operations
Add'l Income/Expense Items (853) (4,597) 129 271
Earnings Before Interest and Tax (18,655) (17,171) (7,008) (15,227)
Interest Expense 36 247 388 362
Earnings Before Tax (18,691) (17,418) (7,396) (15,589)
Income Tax (23) (10) 206 (30)
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (18,668) (19,146) (7,602) (15,559)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (18,668) (17,408) (7,602) (15,559)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (18,668) (17,408) (7,602) (15,559)